Literature DB >> 23881037

Lung cancer: Defining standard of care for performance status 2--don't rush.

Cesare Gridelli.   

Abstract

The standard treatment for patients with advanced-stage non-small-cell lung cancer with a performance status of 2 is unclear because of the heterogeneity of this population. Although a recent trial suggests that carboplatin plus pemetrexed improves survival as compared to single-agent pemetrexed, we should be cautious when defining new standards of treatment on the basis of single small trials.

Entities:  

Mesh：

Year:  2013        PMID： 23881037     DOI： 10.1038/nrclinonc.2013.134

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  7 in total

1.  Treatment of patients with advanced non-small-cell lung cancer with performance status of 2: an unsolved issue.

Authors:  Cesare Gridelli
Journal:  Clin Lung Cancer       Date:  2008-11       Impact factor: 4.785

2.  Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  S Peters; A A Adjei; C Gridelli; M Reck; K Kerr; E Felip
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

3.  Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2.

Authors:  Mauro Zukin; Carlos H Barrios; Jose Rodrigues Pereira; Ronaldo De Albuquerque Ribeiro; Carlos Augusto de Mendonça Beato; Yeni Neron do Nascimento; Andre Murad; Fabio A Franke; Maristela Precivale; Luiz Henrique de Lima Araujo; Clarissa Serodio Da Rocha Baldotto; Fernando Meton Vieira; Isabele A Small; Carlos G Ferreira; Rogerio C Lilenbaum
Journal:  J Clin Oncol       Date:  2013-06-17       Impact factor: 44.544

4.  Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel.

Authors:  C Gridelli; A Ardizzoni; T Le Chevalier; C Manegold; F Perrone; N Thatcher; N van Zandwijk; M Di Maio; O Martelli; F De Marinis
Journal:  Ann Oncol       Date:  2004-03       Impact factor: 32.976

5.  Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials.

Authors:  Rogerio Lilenbaum; Victoria M Villaflor; Corey Langer; Kenneth O'Byrne; Mary O'Brien; Helen J Ross; Mark Socinski; Fred B Oldham; Larissa Sandilac; Jack W Singer; Philip Bonomi
Journal:  J Thorac Oncol       Date:  2009-07       Impact factor: 15.609

6.  American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.

Authors:  Christopher G Azzoli; Sherman Baker; Sarah Temin; William Pao; Timothy Aliff; Julie Brahmer; David H Johnson; Janessa L Laskin; Gregory Masters; Daniel Milton; Luke Nordquist; David G Pfister; Steven Piantadosi; Joan H Schiller; Reily Smith; Thomas J Smith; John R Strawn; David Trent; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

7.  Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study.

Authors:  Alessandro Morabito; Vittorio Gebbia; Massimo Di Maio; Saverio Cinieri; Maria Grazia Viganò; Roberto Bianco; Santi Barbera; Luigi Cavanna; Filippo De Marinis; Vincenzo Montesarchio; Raffaele Costanzo; Claudia Sandomenico; Agnese Montanino; Gianfranco Mancuso; Paolo Russo; Angelo Nacci; Pasqualina Giordano; Gennaro Daniele; Maria Carmela Piccirillo; Gaetano Rocco; Cesare Gridelli; Ciro Gallo; Francesco Perrone
Journal:  Lung Cancer       Date:  2013-05-01       Impact factor: 5.705
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.